Atorvastatin Efficacy and Safety in Patients With Ulcerative Colitis

• Status: Not yet recruiting
• Trial end date: 2027-09-20
• Target enrollment: 0
• Participant gender: All

Summary

Metformin is an antidiabetic biguanide drug that acts by promoting glucose uptake and utilization in the liver. Recent studies proved that metformin could reduce colonic inflammation by AMPK-mediated inhibition of p38 mitogen-activated protein kinase (MAPK)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Atorvastatin; Mesalamine

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• Both males and females will be included

• Negative pregnancy test and effective contraception.

Exclusion Criteria:

• Breastfeeding

• Significant liver and kidney function abnormalities

• Colorectal cancer patients

• Patients with severe UC

• Patients taking rectal or systemic steroids

• Patients taking immunosuppressives or biological therapies